Sander Brooks

The selective orexin-2 receptor antagonist seltorexant improves sleep: An exploratory double-blind, placebo controlled, crossover study in antidepressant-treated major depressive disorder patients with persistent insomnia

Sander Brooks, Gabriël E. Jacobs, Peter de Boer et al. · Journal of Psychopharmacology · 2019 · 69 citations

Multiple-dose clinical pharmacology of ACT-541468, a novel dual orexin receptor antagonist, following repeated-dose morning and evening administration

Clemens Muehlan, Sander Brooks, Rob Zuiker et al. · European Neuropsychopharmacology · 2019 · 54 citations

Multiple-dose Clinical Pharmacology, Allergy, Medicine +7

Translational evaluation of novel selective orexin-1 receptor antagonist JNJ-61393215 in an experimental model for panic in rodents and humans

Giacomo Salvadore, Pascal Bonaventure, Anantha Shekhar et al. · Translational Psychiatry · 2020 · 45 citations · Full text

Phase 1 clinical trial of losmapimod in facioscapulohumeral dystrophy: Safety, tolerability, pharmacokinetics, and target engagement

Michelle Mellion, Lucienne Ronco, Cécile L. Berends et al. · British Journal of Clinical Pharmacology · 2021 · 37 citations · Full text

Light Fractionation Significantly Increases the Efficacy of Photodynamic Therapy Using BF-200 ALA in Normal Mouse Skin

Henriëtte S. de Bruijn, Sander Brooks, A. van der Ploeg–van den Heuvel et al. · PLoS ONE · 2016 · 33 citations · Full text